Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Wanbang Biopharma In-Licenses Infant Seizure Treatment from Aucta

publication date: Jul 25, 2019

Jiangsu Wanbang Biopharma, a subsidiary of Fosun Pharma, acquired China rights to an anti-seizure treatment from New Jersey's Aucta Pharma. Last year, the product, Vigabatrin for Oral Solution, was approved in the US, one of very few FDA-approved treatments for infantile spasms (IS) and certain adults with complex partial seizures whose seizures remain uncontrolled by other anti-epileptics. Aucta is currently seeking an import drug license for Vigabatrin from China's NMPA. Wanbang specializes in treatments for endocrinology, cardiovascular and renal conditions. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.